#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adenovirus infection Osteochondrodysplasia Uveal melanoma Osteomyelitis Glomerulonephritis rapidly progressive Brain injury Acute promyelocytic leukaemia Thyroid cancer metastatic HER2 mutant non-small cell lung cancer Eosinophilic oesophagitis Ependymoma Synovial sarcoma Niemann-Pick disease Glomerulonephritis membranoproliferative Oropharyngeal cancer recurrent More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy Turner’s syndrome – Trials in Disease Netherton’s syndrome – Trials in Disease Hereditary optic atrophy – Life with Disease Gastrointestinal stromal tumour Nephrotic syndrome Synovial sarcoma metastatic – Diagnostics Cystic fibrosis lung – Trials in Disease Chondrosarcoma – Trials in Disease Phenylketonuria – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gt005 Itacitinib Ziclumeran SOVATELTIDE Sodium Oxybate Meropenem Anhydrous Lorazepam Amiloride Hydrochloride Desvenlafaxine Benzoate Belinostat Fluorometholone Doxecitine Ltp001 Vancomycin Exenatide BIIB115 Prednisolone Sodium Phosphate Cerebrolysin Concentrate Dexpanthenol Alpelisib More therapies…

    Learn about Your Condition

    Pseudomyxoma peritonei Toxic nodular goitre Hypothyroidism Nephroblastoma Fracture infection Breast cancer stage II Uterine cancer Depression Colorectal adenoma Pancreatitis chronic Coronary artery occlusion Eructation Cutaneous lupus erythematosus Synovitis Inflammatory bowel disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study of Datopotamab Deruxtecan for Patients with Triple-Negative Breast Cancer and New or Worsening Brain Metastases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    Austria Ireland

  • Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Necvax-Neo1
    • Paclitaxel Albumin-Bound
    Germany

  • Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Atezolizumab
    • Cyclophosphamide Monohydrate
    • Vinorelbine
    Italy

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Pembrolizumab
    France

  • Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Ovarian cancer
    • Triple negative breast cancer
    Investigated Drugs:
    • Farletuzumab Ecteribulin
    • Lenvatinib
    France Spain

  • Study on Pembrolizumab with Chemotherapy for Early-Stage Triple-Negative Breast Cancer in Patients with High TILs

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Filgrastim
    • Glatiramer Acetate
    Portugal
Previous Page
1 2 3 4 5 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!